Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 248 Derosa L., Iebba V., Silva C.A.C., Piccinno G., Wu G., Lordello L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., Marmorino F., Fidelle M., Messaoudene M., Thomas A.M., Gerard Zalcman G., Friard S., Julien Mazieres J., Audigier-Valette C., Moro-Sibilot D., Goldwasser F., Scherpereel A., Pegliasco H., François Ghiringhelli F., Nicole Bouchard N., Cissé Sow C., Darik I., Zoppi S., Ly P., Reni A., Daillère R., Deutsch E., Lee K.A., Laura A., Bolte L.A., Björk J.R., Weersma R.K., Barlesi F., Padilha L., Finzel A., Isaksen M.L., Escudier B., Albiges L., Planchard D., André F., Cremolini C., Martinez S., Besse B., Zhao L.P., Segata N., Wojcik J., Guido Kroemer G., and Laurence Zitvoge L., 2024, Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome, Cell, 187(13): 3373-3389. Dersh D., Hollý J., and Yewdell J.W., 2021, A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion, Nature Reviews Immunology, 21(2): 116-128. https://doi.org/10.1038/s41577-020-0390-6 Duffy M.J., and Crown J., 2019, Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients, Clinical Chemistry, 65(10): 1228-1238. https://doi.org/10.1373/clinchem.2019.303644 Durando M.L., Menghani S.V., Baumann J.L., Robles D.G., Day T.A., Vaziri C., and Scott A.J., 2022, Four-year disease-free remission in a patient with POLE mutation-associated colorectal cancer treated using Anti-PD-1 therapy, Journal of the National Comprehensive Cancer Network, 20(3): 218-223. Fan L., Li Y., Chen J.Y., Zheng Y.F., and Xu X.M., 2019, Immune checkpoint modulators in cancer immunotherapy: recent advances and combination rationales, Cancer Letters, 456: 23-28. https://doi.org/10.1016/j.canlet.2019.03.050 PMID: 37464378 PMCID: PMC10354966 Fang X.F., Zhong C.H., Weng S.S., Hu H.G., Wang J., Xiao Q., Wang, J.W., Sun L.F., Xu, D., Liao X.J., Dong C.X., Suzhan Zhang S.Z., Li J., Ding K.F. and Yuan Y., 2023, Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study, BMC Cancer, 23(1): 676. https://doi.org/10.1186/s12885-023-11139-z Frigerio S., Lartey D.A., D'Haens G.R., and Grootjans J., 2021, The role of the immune system in ibd-associated colorectal cancer: from pro to anti-tumorigenic mechanisms, International Journal of Molecular Sciences, 22(23): 12739. https://doi.org/10.3390/ijms222312739 Fu C.H., Tian G.E., Duan J.Y., Liu K., Zhang C., Yan W.Q., and Wang Y., 2021, Therapeutic antitumor efficacy of cancer stem cell-derived DRibble vaccine on colorectal carcinoma, International Journal of Medical Sciences, 18(14): 3249-3260. https://doi.org/10.7150/ijms.61510 Fukuoka S., Hara H., Takahashi N., Kojima T., Kawazoe A., Asayama M., Yoshii T., Kotani D., Tamura H., Mikamoto Y., Hirano N., Wakabayashi M., Nomura S., Sato A., Kuwata T., Togashi Y., Nishikawa H., and Shitara K., 2020, Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib Trial (REGONIVO, EPOC1603), Journal of Clinical Oncology, 38(18): 2053-2061. https://doi.org/10.1200/JCO.19.03296 Galli F., Varani M., Lauri C., Silveri G.G., Onofrio L., and Signore A., 2021, Immune cell labelling and tracking: implications for adoptive cell transfer therapies, EJNMMI Radiopharmacy and Chemistry, 6(1): 1-9. https://doi.org/10.1186/s41181-020-00116-7 PMID: 33537909 PMCID: PMC7859135 Garmezy B., Ghisoni E., Genta S., Scotto G., Tuninetti V., Turinetto M., and Valabrega G., 2020, Immuno-metabolism and microenvironment in cancer: key players for immunotherapy, International Journal of Molecular Sciences, 21(12): 4414. https://doi.org/10.3390/ijms21124414 PMID: 32575899 PMCID: PMC7352562 Giatromanolaki A., Kavazis C., Gkegka A.G., Kouroupi M., Tsaroucha A., Pitiakoudis M., and Koukourakis M.I., 2023, Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy, Immunobiology, 228(6): 152756. https://doi.org/10.1016/j.imbio.2023.152756 Golstein P., and Griffiths G.M., 2018, An early history of T cell-mediated cytotoxicity, Nature reviews Immunology, 18(8): 527-535. https://doi.org/10.1038/s41577-018-0009-3 Grasso C.S., Giannakis M., Wells D.K., Hamada T., Mu X.J., Quist M., Nowak J.A., Nishihara R., Qian Z.R., Inamura K., Morikawa T., Nosho K., Gabriel Abril-Rodriguez G., Connolly C., Escuin-Ordinas H., Geybels M.S., William M. Grady W.M., Hsu L., Hu-Lieskovan S., Huyghe J.R., Kim Y.J., Krystofinski P., Leiserson M.D.M., Montoya D.J., Nadel B.B., Pellegrini M., Pritchard C.C., Puig-Saus C., Quist E.H., Raphael B.J., Salipante S.J., Shin D.S., Shinbrot E., Shirts B., Shukla S., Stanford J.L., Sun W., Tsoi J., Alexander Upfill-Brown A., Wheeler D.A., Wu C.J., Yu M., Zaidi S.H., Zaretsky J.M., Gabriel S.B., Eric S. Lander E.S., Garraway L.A., Hudson T.J., Fuchs C.S., Ribas A., Ogino S., and Peters U., 2018, Genetic mechanisms of immune evasion in colorectal cancer, Cancer Discovery, 8: 730-749. https://doi.org/10.1158/2159-8290.CD-17-1327 PMID: 29510987 PMCID: PMC5984687 Gomez S., Tabernacki T., Kobyra J., Roberts P., and Chiappinelli K.B., 2020, Combining epigenetic and immune therapy to overcome cancer resistance, Seminars in Cancer Biology, 65: 99-113. https://doi.org/10.1016/j.semcancer.2019.12.019
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==